David's practice is predominantly in the areas of chemical and biomedical research tools, including analytical instrumentation, and pharmaceuticals. David's experience in these areas includes GB and European patent prosecution, drafting and international portfolio management for large corporations and universities. David also has significant experience in oppositions and appeals before the EPO. Other subject matter that falls within David's practice includes medical devices, nanotechnology and advanced materials.
David has a degree in Chemistry and a doctorate in Chemistry, as well as a law degree from the University of New South Wales. His research experience included the construction of a novel mass spectrometer, and the application of mass spectrometry to proteomics and analysis of post-translation modification of proteins. His research experience thus covers development of instrumentation and methods of chemical analysis, through to characterisation of biological materials.
David qualified as a solicitor in Sydney, Australia, where he worked in IP litigation and has also qualified as a solicitor in England and Wales. David's practice draws on this combination of scientific and legal experience, with his understanding of enforcement and opposition informing his patent drafting and prosecution, and assisting David in providing commercially focused advice in all areas of his practice.
BSc in Chemistry with Hons 1
Bachelors of laws, UNSW
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.